Dutch-English LEMS Tumor Association Prediction (DELTA-P) Score
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Very Low Risk0–1
- Low-Moderate Risk2–2
- High Risk3–6
The Dutch-English LEMS Tumor Association Prediction (DELTA-P) Score calculator is designed for bedside predicting small-cell lung cancer (SCLC) in patients with Lambert-Eaton myasthenic syndrome (LEMS) using clinical parameters assessed at or within 3 months of onset in clinical practice. The resulting score directly guides clinician.
Clinical Guidelines & Evidence
Predicts small-cell lung cancer (SCLC) in patients with Lambert-Eaton myasthenic syndrome (LEMS) using clinical parameters assessed at or within 3 months of onset. The score helps identify high-risk patients requiring intensive cancer screening.
Clinical Indication
The Dutch-English LEMS Tumor Association Prediction (DELTA-P) Score is indicated for bedside clinical practice to support Predicts small-cell lung cancer (SCLC) in patients with Lambert-Eaton myasthenic syndrome (LEMS) using clinical parameters assessed at or within 3 months of onset. The score helps identify high-risk patients requiring intensive cancer screening.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Treatment of underlying SCLC can improve LEMS symptoms in some patients..
DELTA-P Score = Sum of points for: Age ≥50 years (1 point) + Current smoking (1 point) + Weight loss >5% (1 point) + Bulbar involvement (1 point) + Erectile dysfunction in males (1 point) + Karnofsky performance status <70 (1 point). Score ranges from 0-6 points with higher scores indicating increased SCLC risk.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age_at_onset | string | Yes | Age at onset of LEMS symptoms |
| smoking_status | string | Yes | Smoking status at time of LEMS diagnosis |
| weight_loss | string | Yes | Weight loss of more than 5% at or within 3 months of LEMS onset |
| bulbar_involvement | string | Yes | Presence of bulbar symptoms (dysphagia, dysarthria, ptosis, diplopia) at or within 3 months of onset |
| erectile_dysfunction | string | Yes | Presence of erectile dysfunction in male patients at or within 3 months of onset (score as 'no' for female patients) |
| karnofsky_status | string | Yes | Karnofsky performance status at or within 3 months of LEMS onset |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1 | Very Low Risk | SCLC virtually excluded |
| 2–2 | Low-Moderate Risk | Low to moderate SCLC risk |
| 3–6 | High Risk | High SCLC risk - intensive screening required |
Evidence-Based References (EBM)
- Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 2008;26(26):4276-81. doi: 10.1200/JCO.2008.17.1302.DOI: 10.1200/JCO.2008.17.1302
- Titulaer MJ, Klooster R, Potman M, Sabater L, Graus F, Hegeman IM, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol. 2009;27(26):4260-7. doi: 10.1200/JCO.2008.20.6169.DOI: 10.1200/JCO.2008.20.6169
- Titulaer MJ, Maddison P, Sont JK, Wirtz PW, Hilton-Jones D, Klooster R, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29(7):902-8. doi: 10.1200/JCO.2010.32.0440.DOI: 10.1200/JCO.2010.32.0440
- van Sonderen A, Wirtz PW, Verschuuren JJ, Titulaer MJ. Paraneoplastic syndromes of the neuromuscular junction: therapeutic implications. Brain. 2016;139(Pt 10):2759-71. doi: 10.1093/brain/aww199.DOI: 10.1093/brain/aww199